Stay updated on Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.

Latest updates to the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now displays a revision tag updated to Revision: v3.4.2, replacing Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check15 days agoChange DetectedRevision 3.4.1 was added; the previous funding/operating-status notice associated with Revision 3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check30 days agoChange DetectedAdded a 'Show glossary' option and updated UI labels, including 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', plus a new 'Revision: v3.4.0' tag.SummaryDifference0.1%

- Check37 days agoChange DetectedA new revision label, Revision: v3.3.4, was added and the previous Revision: v3.3.3 was removed.SummaryDifference0.0%

- Check65 days agoChange DetectedExpanded the study's Locations section to include a comprehensive list of site locations across multiple regions. The update covers locations across the United States, Canada, Australia, and numerous other countries.SummaryDifference2%

- Check87 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.3.1 was removed. This update changes only metadata/version information and does not affect study details or page functionality.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Renal Cell Carcinoma Adjuvant Clinical Trial page.